Fatal airway inflammation induced by pembrolizumab in a patient with NSCLC
T Ogawa, J Miyata, J Maehara, T Inoue… - Journal of Thoracic …, 2019 - jto.org
To the Editor: Pembrolizumab, which is a humanized monoclonal antibody against the
programmed death 1 (PD-1) protein, has been approved for the treatment of patients with
previously untreated, advanced NSCLC where more than 50% of the tumor cells are positive
for programmed death-ligand 1. 1 Pembrolizumab can lead to a unique spectrum of side
effects, termed immune-related adverse events (irAEs). 2 Herein, we describe a patient who
developed fatal airway inflammation under anti–PD-1 immunotherapy with pembrolizumab …
programmed death 1 (PD-1) protein, has been approved for the treatment of patients with
previously untreated, advanced NSCLC where more than 50% of the tumor cells are positive
for programmed death-ligand 1. 1 Pembrolizumab can lead to a unique spectrum of side
effects, termed immune-related adverse events (irAEs). 2 Herein, we describe a patient who
developed fatal airway inflammation under anti–PD-1 immunotherapy with pembrolizumab …